Sanofi, GSK to supply up to 60 million doses of Covid-19 vaccine to UK

PARIS (Reuters) - Sanofi and GSK said they had reached an agreement with Britain to supply it with up to 60 million doses of a potential COVID-19 vaccine, and that discussions with other governments were ongoing. No vaccine has yet been approved to treat or prevent COVID-19, the respiratory disease caused by the new coronavirus which has killed more than 659,000 people and triggered economic havoc worldwide.

Financial terms of the agreement were not disclosed. Sanofi and GSK, which had first teamed up in April, confirmed in a statement.

This article is no longer available in our repository.

There could be multiple reasons for this.